Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sotagliflozin - Lexicon Pharmaceuticals/Sanofi

Drug Profile

Sotagliflozin - Lexicon Pharmaceuticals/Sanofi

Alternative Names: [14C]-LX4211; LP-802034; LX-4211; SAR 439954; Zynquista

Latest Information Update: 14 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lexicon Pharmaceuticals
  • Developer Lexicon Pharmaceuticals; Sanofi
  • Class Alcohols; Antihyperglycaemics; Cardiovascular therapies; Glycosides; Pyrans; Small molecules; Sulfhydryl compounds
  • Mechanism of Action Sodium-glucose transporter 1 inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Type 1 diabetes mellitus
  • Phase III Cardiovascular disorders; Type 2 diabetes mellitus
  • Phase II Heart failure

Most Recent Events

  • 17 Jan 2019 Sanofi expects EMA approval decision for sotagliflozin for Type-1 diabetes mellitus in the first half of 2019
  • 17 Jan 2019 Sanofi plans a phase I bioavailability trial for Type 2 diabetes mellitus (In volunteers) (PO) (NCT03802487)
  • 14 Jan 2019 Phase-I clinical trials in Type 2 diabetes mellitus (In volunteers) in United Kingdom (PO) (EudraCT2017-004937-94, NCT03802487)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top